Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.82 |
| ▸ | RAB9A | P51151 | 1/20 | 0.82 |
| ▸ | GAA | P10253 | 4/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.79 |
| ▸ | CASP1 | P29466 | 1/20 | 0.79 |
| ▸ | CASP7 | P55210 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | KIF11 | P52732 | 1/20 | 0.66 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15976549 | 0.91 | GAA (0.77) | TSHRRAB9AGAAHSD17B10ALOX15 | |
| SCHEMBL26671643 | 0.90 | TSHR (0.75) | TSHRRAB9AGAAHSD17B10ALOX15 | |
| SCHEMBL4648036 | 0.90 | GAA (0.77) | TSHRRAB9AGAAHSD17B10ALOX15 | |
| SCHEMBL4669190 | 0.87 | ALDH1A1 (0.67) | TSHRRAB9AGAAHSD17B10ALOX15 | |
| SCHEMBL26671709 | 0.87 | TSHR (0.70) | TSHRRAB9AGAAHSD17B10ALOX15 | |
| SCHEMBL29794092 | 0.87 | TSHR (0.70) | TSHRRAB9AGAAHSD17B10ALOX15 | |
| SCHEMBL3392657 | 0.84 | GAA (0.76) | GAAHSD17B10MEN1KMT2ALMNA | |
| SCHEMBL19752718 | 0.84 | GAA (0.76) | GAAHSD17B10MEN1KMT2ALMNA | |
| SCHEMBL26820227 | 0.84 | TSHR (0.64) | TSHRRAB9AGAAHSD17B10ALOX15 | |
| SCHEMBL26671646 | 0.84 | TSHR (0.64) | TSHRRAB9AGAAHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106632071-B | Method for preparing 3, 4-dihydropyrimidine-2-one derivative by promoting high-efficiency catalysis of titanocene dichloride with ethanol | 陕西师范大学 | 2021-07-09 | — | — | CN | disclosed |
| US-8389529-B2 | Methods and compositions for treating asthma | HYDRA BIOSCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389529-B2 | Methods and compositions for treating asthma | HYDRA BIOSCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8178542-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178542-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | TSHR 4859/4885RAB9A 3906/4885GAA 876/4885 |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | TRPA1, TRPV1, TRPV2 | TSHR 2721/4885RAB9A 2520/4885GAA 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.